The HealthCare Segment at Bayer (BAYRY) has been the key revenue generator at the company for the last few years. The segment is involved in the research, development, manufacturing and marketing of products for the prevention, diagnosis and treatment of diseases. The segment contributed around 46.7% of total revenues of €39.8 billion in 2012.
Bayer’s HealthCare segment announced encouraging results from the PEripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths (PEARL) registry on its AngioJet Ultra thrombectomy system a few days back.
The system was studied for the treatment of peripheral venous and arterial diseases. Data revealed that AngioJet Ultra thrombectomy system established an immediate improvement in blood flow in over 90% of the vessels treated.
An 89% limb salvage rate was also observed in AngioJet Ultra Thrombectomy System treated patients suffering from acute limb ischemia. Moreover, 84% of the patients suffering from deep vein thrombosis (DVT) were free from reoccurrence 12 months after the treatment.
Data further revealed that statistically significant improvements were observed in the quality of life following treatment with the system. Moreover, AngioJet Ultra Thrombectomy System treatment reduced the cost of DVT treatment.
We are encouraged by the string of good news coming from Bayer’s HealthCare segment in recent times. We expect the segment to continue to drive growth at the company in the coming years.
Bayer, a large-cap pharma company, presently carries a Zacks Rank #2 (Buy). Large-cap peers like Eli Lilly and Co. (LLY) and Novo Nordisk (NVO) appear to be equally attractive. Roche (RHHBY) appears to be more attractive in the large cap pharma space with a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment